Maladie
Lung cancer
ICD-10 : C34 — Malignant neoplasm of bronchus and lung
Chiffres clés
Valeurs publiées uniquement. Chaque tuile ouvre la section qui porte sa source, son année et sa référence.
- Fourchettes de coûts de traitement 5 fourchettes publiées, chacune avec sa source sur la page de la ligne
- Survie à cinq ans 28.7% 95% CI 28.6–28.9 · 2019–2021
- Hôpitaux disposant d’une source publiée 8 pour cette maladie, chacun avec sa source publiée
- Essais cliniques 141 en recrutement ou pas encore en recrutement, selon les publications
Détails de la maladie
- Nom anglais
- Malignant neoplasm of bronchus and lung
Également appelé
- NSCLC
- SCLC
Fourchettes de coûts de traitement
Chaque fourchette ci-dessous est publiée sur une même base de facturation : Avant remboursement. Les sources ne publient aucun chiffre après remboursement ; aucun n'est donc affiché ici.
| Parcours de traitement | Fourchette de coûts | Base du prix | Année des données |
|---|---|---|---|
| Chirurgie | 52000 – 81790 CNY | Forfait par pathologie | 2020–2025 |
| Radiothérapie | 19000 – 58000 CNY | Tarif par acte | 2025–2026 |
| Chimiothérapie | 6550 – 9500 CNY | Forfait par pathologie | 2020–2021 |
| Thérapie ciblée | 20000 – 60000 CNY | Tarif par acte | 2024–2025 |
| Immunothérapie | 32043 – 43803 CNY | Tarif par acte | 2024–2025 |
Les barres partagent une même échelle pour les lignes ci-dessus : chacune commence au chiffre inférieur publié de sa ligne et se termine à son chiffre supérieur. Le chiffre supérieur le plus élevé de cette page est 81790 CNY. Chaque ligne conserve son année de données et sa référence.
5 fourchettes de coûts pour cette maladie, chacune avec sa source sur la page de la ligne.
Les valeurs rédigées en chinois sont citées telles que publiées par la source.
Survie à cinq ans
Taux de survie à 5 ans 28.7% IC à 95 % 28.6–28.9
- Population
- Global (tous stades confondus) · Survie relative standardisée selon l’âge
- Période
- 2019–2021
- Éditeur
- Centre national du cancer
- Nature de la valeur
- Valeur estimée (analyse hybride)
- Périmètre du registre
- 281 registres du cancer de population
- Disponibilité des données par stade
- Non publié par stade (la source ne publie que le chiffre global)
Les valeurs rédigées en chinois sont citées telles que publiées par la source.
Comment lire ce chiffre. Ce chiffre est publié pour tous les stades confondus ; il s'agit donc d'une moyenne sur l'ensemble des personnes des données du registre national, non d'un pronostic pour une personne. Pour la plupart des cancers, le stade au diagnostic est le facteur unique le plus fort des différences de survie : la survie est généralement plus élevée lorsque le cancer est détecté à un stade précoce et plus faible lorsqu'il est détecté plus tard. Les comparaisons entre cancers dépendent aussi de la précocité ou de la tardiveté à laquelle chacun tend à être diagnostiqué ; un chiffre plus bas ne signifie donc pas en soi des soins moins bons.
Le chiffre est une survie relative : il compare les personnes diagnostiquées avec ce cancer à des personnes du même âge et du même sexe dans la population générale, et il est standardisé selon l'âge ; ce n'est donc pas la part de patients encore vivants après cinq ans. Il est publié comme valeur estimée (analyse hybride) car les rapports des registres arrivent avec un décalage ; le Centre national du cancer a donc modélisé la période la plus récente. Pour situer, la même source publie une survie relative à cinq ans de 43,7 % pour l'ensemble des cancers en 2019–2021.
Hôpitaux disposant d'un dossier publié pour cette maladie
Sélectionnés à partir de sources de données publiques officielles
Ces hôpitaux sont sélectionnés à partir de sources de données publiques officielles — les classements de réputation par spécialité de l'université Fudan, la liste des spécialités cliniques clés nationales et les centres nationaux de recherche clinique — afin que chaque ligne d'une fiche puisse être vérifiée dans sa source publiée. Il ne s'agit pas d'une inscription payante ou promue.
Comment ces hôpitaux ont été sélectionnés
Admission. Un hôpital est listé pour une maladie lorsque la spécialité à laquelle cette maladie est rattachée porte au moins l'un des éléments suivants : une place ou une nomination dans le classement de réputation par spécialité de l'université Fudan ; un titre de spécialité clinique clé nationale de niveau A, B ou C ; ou un centre national de recherche clinique ou un laboratoire clé d'État dans cette spécialité. L'accréditation JCI est affichée comme un badge ; elle ne détermine jamais l'admission et ne détermine jamais l'ordre.
Ordre. Étape 1 : une place Fudan entre 1 et 10 pour la spécialité. Étape 2 : une autre place Fudan, ou une nomination. Étape 3 : un titre de spécialité clinique clé nationale de niveau A. Étape 4 : un titre de spécialité clinique clé nationale de niveau B. Étape 5 : un centre national de recherche clinique ou un laboratoire clé d'État dans la spécialité, un centre avant un laboratoire. Étape 6 : un titre de spécialité clinique clé nationale de niveau C, qui est un enregistrement que nous publions sans source officielle indépendante et qui figure donc après les autres.
Égalités. Au sein d'une même étape : la meilleure place Fudan d'abord, puis le niveau de spécialité clé le plus fort (A avant B avant C), puis la province, puis la ville, puis le nom de l'hôpital — le même ordre province-ville-nom que celui utilisé par le répertoire des hôpitaux. Huit hôpitaux au maximum sont listés.
Lorsque la liste est courte. Cinq hôpitaux ou plus : les huit premiers sont listés. Trois ou quatre : tous sont listés, et un volet supplémentaire ajoute les autres enregistrements jusqu'à huit, chacun portant son niveau de preuve. Un ou deux : de même, avec ce volet ouvert et une ligne indiquant combien d'hôpitaux disposent d'un dossier public solide. Aucun : la page indique qu'aucun dossier public solide n'a été trouvé et renvoie au répertoire de la spécialité. Une place, un établissement ou un décompte ne sont jamais inventés pour remplir la liste.
Les classements Fudan sont le classement de réputation par spécialité le plus largement reconnu par les cliniciens chinois, publié chaque année par l'institut de gestion hospitalière de l'université Fudan.
-
First Affiliated Hospital of Guangzhou Medical University
Classement de réputation par spécialité de Fudan 2023
- Chirurgie thoracique #5 https://www.fdygs.com/news2023-1.aspx
- Pneumologie #1 https://www.fdygs.com/news2023-1.aspx
Spécialité clinique clé nationale
- Pneumologie (niveau B) https://www.gyfyyy.cn/cn/news/xwsd/index_88.html
- Chirurgie thoracique (niveau B) https://www.gyfyyy.cn/cn/news/xwsd/index_88.html
Plateforme de recherche
- Centre national de recherche clinique sur les maladies respiratoires https://www.most.gov.cn/tztg/201306/t20130608_106459.html
Recherches publiées
- From phenotypic associations to clinical triage: promise and pitfalls of fusion-prediction models in non-small cell lung cancer. Journal of thoracic disease, 2026
- Development of clinical-radiological prediction models to prioritize ALK, ROS1, and RET fusion testing in major driver alteration-negative non-small cell lung cancer. Journal of thoracic disease, 2026
4 études publiées supplémentaires
PubMed indexe 6 articles sur cette maladie qui nomment cet hôpital.
Également classé : Urologie nommé dans la liste Fudan.
-
Cancer Hospital of Chinese Academy of Medical Sciences
Classement de réputation par spécialité de Fudan 2023
- Chirurgie thoracique #1 https://www.fdygs.com/news2023-1.aspx
Spécialité clinique clé nationale
- Chirurgie thoracique (niveau B) https://www.cicams.ac.cn/news/401.html
Recherches publiées
- A plain language summary of results from the CHOICE-01 trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC). Future oncology (London, England), 2025
- Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial. Signal transduction and targeted therapy, 2024
3 études publiées supplémentaires
PubMed indexe 5 articles sur cette maladie qui nomment cet hôpital.
Également classé : Oncologie médicale #1, Urologie nommé dans la liste Fudan.
-
Shanghai Chest Hospital
Classement de réputation par spécialité de Fudan 2023
- Chirurgie thoracique #2 https://www.fdygs.com/news2023-1.aspx
Spécialité clinique clé nationale
- Chirurgie thoracique (niveau B) https://www.shxkyy.com/hz/list/190/1400.html
Recherches publiées
- Best practices for respiratory function training in perioperative patients with lung cancer: A scoping review and evidence synthesis. Asia-Pacific journal of oncology nursing, 2026
- Patient-reported outcomes with a personalized follow-up program after lung cancer resection: A single-center randomized controlled trial. Asia-Pacific journal of oncology nursing, 2026
3 études publiées supplémentaires
PubMed indexe 5 articles sur cette maladie qui nomment cet hôpital.
-
China-Japan Friendship Hospital
Classement de réputation par spécialité de Fudan 2023
- Pneumologie #2 https://www.fdygs.com/news2023-1.aspx
- Chirurgie thoracique nommé https://www.fdygs.com/news2023-1.aspx
Spécialité clinique clé nationale
- Pneumologie (niveau B) https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
- Chirurgie thoracique (niveau B) https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Recherches publiées
- Development and validation of an interpretable model for pre-chemotherapy triage of fatigue-pain-sleep disturbance burden in lung cancer. European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2026
- CLIC4 inhibits the progression of non-small cell lung cancer by suppressing the MAPK pathway. Scientific reports, 2026
2 études publiées supplémentaires
PubMed indexe 4 articles sur cette maladie qui nomment cet hôpital.
-
West China Hospital, Sichuan University
Classement de réputation par spécialité de Fudan 2023
- Chirurgie thoracique #4 https://www.fdygs.com/news2023-1.aspx
- Pneumologie #3 https://www.fdygs.com/news2023-1.aspx
Spécialité clinique clé nationale
- Pneumologie (niveau A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
- Chirurgie thoracique (niveau A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Également classé : Chirurgie générale #3, Urologie #2 (ex æquo), Oto-rhino-laryngologie #8 dans la liste Fudan.
-
Shanghai Pulmonary Hospital
Classement de réputation par spécialité de Fudan 2023
- Chirurgie thoracique #3 https://www.fdygs.com/news2023-1.aspx
- Pneumologie nommé https://www.fdygs.com/news2023-1.aspx
Spécialité clinique clé nationale
- Pneumologie (niveau B) https://www.shsfkyy.com/gzb/list/b980f2cf4b134e5d85397ced965ce260/74344ed2746449a68d71c2b76c8cf423.html
- Chirurgie thoracique (niveau B) https://www.shsfkyy.com/gzb/list/b980f2cf4b134e5d85397ced965ce260/74344ed2746449a68d71c2b76c8cf423.html
Recherches publiées
- Integrating proteomics and metabolomics to reveal MAT2A for metabolic reprogramming in non-small cell lung cancer cells. iScience, 2026
- SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial. Cancer cell, 2026
11 études publiées supplémentaires
PubMed indexe 13 articles sur cette maladie qui nomment cet hôpital.
-
Peking Union Medical College Hospital
Classement de réputation par spécialité de Fudan 2023
- Pneumologie #4 https://www.fdygs.com/news2023-1.aspx
- Chirurgie thoracique nommé https://www.fdygs.com/news2023-1.aspx
Également classé : Chirurgie générale #1, Urologie #8, Gynécologie #1 dans la liste Fudan.
-
Ruijin Hospital
Classement de réputation par spécialité de Fudan 2023
- Chirurgie thoracique #7 (ex æquo) https://www.fdygs.com/news2023-1.aspx
- Pneumologie #5 https://www.fdygs.com/news2023-1.aspx
Spécialité clinique clé nationale
- Pneumologie (niveau B) https://www.rjh.com.cn/2018RJPortal/lcyxy2019/sy/jj/index.shtml
Recherches publiées
- Recent Advances and Future Challenges of Bispecific Antibodies in Lung Cancer. Critical reviews in oncology/hematology, 2026
- Attenuated Salmonella typhimurium VNP20009 L-forms suppress tumor growth and metastasis by inhibiting TGF-β1/Snail/Vimentin pathway in murine lung cancer. European journal of pharmacology, 2026
PubMed indexe 2 articles sur cette maladie qui nomment cet hôpital.
Également classé : Chirurgie générale #4, Maladies infectieuses #6, Médecine nucléaire #10 dans la liste Fudan.
Essais cliniques (traitements expérimentaux)
En complément des soins standards, des études de recherche clinique sur Lung cancer peuvent actuellement être ouvertes aux participants en Chine. Les traitements à l'étude n'ont pas été approuvés par le régulateur comme traitement standard — il s'agit de recherche clinique, non de soins courants. Chaque fiche nomme l'investigateur principal et l'hôpital qui mène l'étude. Si cela vous intéresse, contactez l'hôpital pour vous renseigner sur l'éligibilité et décider vous-même de candidater.
-
Étude A Randomized, Double-Blind, Placebo-Controlled, Multi-Regional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy
- Hôpital
- Third Affiliated Hospital of Harbin Medical University
- Statut
- En recrutement
- Registre
- NCT06095583
-
Étude A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer
- Hôpital
- Peking University Shenzhen Hospital
- Statut
- En recrutement
- Registre
- NCT07480213
-
Étude A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy
- Investigateur principal
- Qiming Wang · Director
- Hôpital
- Henan Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07559786
-
Étude Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy: a Multicenter Randomized Controlled Phase III Clinical Trial
- Investigateur principal
- Jinming Yu · Director of Shandong Cancer Hospital and Institute
- Hôpital
- Shandong Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT04829708
-
Étude Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
- Investigateur principal
- Wei Zhang · Chief Physician
- Hôpital
- Shanghai Chest Hospital
- Statut
- En recrutement
- Registre
- NCT07070011
136 études enregistrées supplémentaires
-
Étude A Phase II, Single-Arm, Prospective Study of Neoadjuvant Icotinib With Chemotherapy for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable for Stage II to IIIB(N2) Non-small Cell Lung Cancer
- Investigateur principal
- Wu Nan · Principal Investigator
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT05104788
-
Étude A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07413042
-
Étude Neoadjuvant Sintilimab or Combined With Chemotherapy for Stage III Driven Gene Mutation Negative Non-small Cell Lung Cancer
- Investigateur principal
- Peng Zhang · Director of thoracic department
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- En recrutement
- Registre
- NCT04728724
-
Étude Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression
- Investigateur principal
- Chunxia Su · Director of the Clinical Research Center
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- En recrutement
- Registre
- NCT06749860
-
Étude Evaluation of AI-Assisted Versus Conventional Human Reading for Lung Cancer Screening in Community-Based Settings: A Randomized Controlled Trial
- Investigateur principal
- Jianxing He · Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06988579
-
Étude Construction and Evaluation of a Hospital-Community Health Collaboration Model Empowered by Digital Technology for Lung Cancer Screening
- Investigateur principal
- Jianxing He · Director
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06988943
-
Étude Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.
- Investigateur principal
- Jianxing He · Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06843707
-
Étude Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial
- Investigateur principal
- Chang Chen
- Statut
- En recrutement
- Registre
- NCT05053802
-
Étude A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer
- Hôpital
- The First Affiliated Hospital, Sun Yat-sen University
- Statut
- En recrutement
- Registre
- NCT07227025
-
Étude A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumor Efficacy and Safety of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery (WU-KONG16)
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07182682
-
Étude Phase II Study of Neoadjuvant CT-Guided Intra-tumor Double Checkpoint Blockades for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection
- Hôpital
- The Second Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06492421
-
Étude A Phase III, Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
- Hôpital
- Sun Yat-sen University Cancer Center
- Statut
- En recrutement
- Registre
- NCT07739758
-
Étude Efficacy and Safety of Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy as Neoadjuvant Treatment for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer: A Multicenter, Single-Arm, Prospective Phase II Clinical Trial
- Investigateur principal
- Hu Liao · Deputy Director & Medical Team Leader, Department of Thoracic Surgery, West China Hospital, Sichuan University; Associate Professor of Surgery; Master's Supervisor
- Hôpital
- The Third People's Hospital of Chengdu
- Statut
- En recrutement
- Registre
- NCT07855965
-
Étude A Phase 1/2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and/or GD2 in Adults With Relapsed/Refractory Small Cell Lung Cancer
- Hôpital
- Peking University Shenzhen Hospital
- Statut
- En recrutement
- Registre
- NCT07744256
-
Étude A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06793215
-
Étude A Prospective, Single Arm, Phase II Clinical Study of Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
- Investigateur principal
- Wei Zhou · Department Director
- Hôpital
- Chongqing University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07425795
-
Étude Immunonutrition in Reducing Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer: a Prospective, Randomized, Controlled, Open-label Clinical Trial
- Investigateur principal
- HuaiLiu · Prof.
- Hôpital
- Hunan Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT06840704
-
Étude A Phase Ib/III Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer
- Hôpital
- Tianjin Medical University Cancer Institute & Hospital
- Statut
- En recrutement
- Registre
- NCT06417008
-
Étude A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
- Hôpital
- Shanghai Chest Hospital
- Statut
- En recrutement
- Registre
- NCT06903377
-
Étude A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy：A Phase II Trial
- Investigateur principal
- Xuwei Cai · Director
- Hôpital
- Shanghai Chest Hospital
- Statut
- En recrutement
- Registre
- NCT07091305
-
Étude A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- En recrutement
- Registre
- NCT07444437
-
Étude Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Single-arm, Phase 2 Trial
- Investigateur principal
- Peng Zhang · Director
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- En recrutement
- Registre
- NCT06256237
-
Étude Exploration on the Value of Molecular Residual Disease Based on Circulating Tumor DNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
- Investigateur principal
- Peng Zhang · Professor
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- En recrutement
- Registre
- NCT05965024
-
Étude Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung Cancer: a Prospective, Observational Study
- Investigateur principal
- Chang Chen · Deputy Director of MD. PhD. Program in Thoracic Surgery, Secretary of the party committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- En recrutement
- Registre
- NCT07328945
-
Étude Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy Study of the Combination Therapy With HC010 for Injection in Patients With Advanced Solid Tumors:A Multicenter, Open-Label, Dose Range-Finding and Multiple Cohort Dose Expansion Phase Ib Clinical Trial-Lung Cancer Population
- Hôpital
- Sun Yat-sen University Cancer Center
- Statut
- En recrutement
- Registre
- NCT07381829
-
Étude A Prospective, Single-arm, Multicenter, Phase II Clinical Study on Envafolimab Combined With Disitamab Vedotin And Carboplatin for Resectable, Stage II-III, HER2-Mutant Non-Small Cell Lung Cancer
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- En recrutement
- Registre
- NCT06734182
-
Étude A Multicenter Phase II/III Study Evaluating the Efficacy and Safety of SCTB41 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Driver-Negative Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- En recrutement
- Registre
- NCT07662395
-
Étude A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Hôpital
- The First Affiliated Hospital of Anhui Medical University
- Statut
- En recrutement
- Registre
- NCT07217301
-
Étude An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Efficacy, and Pharmacokinetics in Participants With Small Cell Lung Cancer
- Hôpital
- The First Affiliated Hospital of Anhui Medical University
- Statut
- En recrutement
- Registre
- NCT06179069
-
Étude Comparison of Segmentectomy Versus Lobectomy for Early-stage Non-small Cell Lung Cancer ≤ 2 cm in the Middle Third of the Lung Field: A Prospective and Multi-center RCT Study
- Hôpital
- Jiangsu Province Hospital
- Statut
- En recrutement
- Registre
- NCT04944563
-
Étude PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Hôpital
- Anhui Provincial Hospital
- Statut
- En recrutement
- Registre
- NCT07144280
-
Étude DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07472517
-
Étude A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT06801834
-
Étude A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT05920356
-
Étude Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients: a Triple Blinded, Randomized Controlled Trial to Assess the Efficacy of Tranexamic Acid for Hemostasis
- Hôpital
- The Second Affiliated Hospital Zhejiang University School of Medicine
- Statut
- En recrutement
- Registre
- NCT06023212
-
Étude A Phase I/II Multicenter, Open Label, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of WSD0922-FU in the Treatment of Advanced Non-small Cell Lung Cancer
- Hôpital
- Anhui Provincial Hospital
- Statut
- En recrutement
- Registre
- NCT06631989
-
Étude Targeting Delta-like Ligand 3 (DLL3) With 68Ga-PFD3 PET/CT for the Diagnosis and Assessment of Small Cell Lung Cancer (SCLC)
- Investigateur principal
- Tingting Yuan · Attending physician
- Hôpital
- Peking University First Hospital
- Statut
- En recrutement
- Registre
- NCT07508852
-
Étude Effectiveness of Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer：A Randomized Controlled Clinical Study
- Investigateur principal
- Liu Zhishun · professer，Chief Physician
- Hôpital
- The First Affiliated Hospital of Anhui Medical University
- Statut
- En recrutement
- Registre
- NCT06926140
-
Étude TCR-T Cells Targeting Cancer Cells for Immunotherapy of Lung Cancer and Other Solid Tumors: Phase I Clinical Trial
- Hôpital
- The Second Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT03778814
-
Étude Observational Study on the Efficacy and Safety of Huaier Granules Compared With Platinum Containing Dual Drug Combination Chemotherapy in Adjuvant Therapy for Resectable Stage II-IIIA Non-small Cell Lung Cancer After Radical Surgery
- Investigateur principal
- Hongxu Liu · professor
- Hôpital
- Liaoning Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT06109454
-
Étude Prospective, Single-arm Phase II Clinical Study of Single-drug Chemotherapy Plus Immunotherapy in Metastatic Non-small Cell Lung Cancer Elderly Patients
- Investigateur principal
- HAN GUANG · Chief physician
- Hôpital
- Hubei Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT06032052
-
Étude ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07361497
-
Étude A Single Arm, Open Label, Dose-escalating, Prospective Phase I Clinical Trial Evaluating the Safety, Tolerability and Efficacy of TMT101 Injection Alone in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC) After Standard Treatment Failure
- Investigateur principal
- Wu Wenming · Director, Chief Physician of Basic Surgery, Principal Investigator, Clinical Professor
- Hôpital
- Peking Union Medical College Hospital
- Statut
- En recrutement
- Registre
- NCT06861543
-
Étude A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Hôpital
- The First Affiliated Hospital of Anhui Medical University
- Statut
- En recrutement
- Registre
- NCT07143045
-
Étude Low-dose Radiation Therapy and Stereotactic Body Radiation Therapy Combined With PD-1 Inhibitor Sintilimab and Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Patients With Locally Advanced or Metastatic Squamous Cell Lung Cancer: A Randomized, Phase II Multicenter Clinical Trial
- Investigateur principal
- You Lu · Chair of Division of Thoracic Tumor Multimodality Treatment
- Hôpital
- The Second Affiliated Hospital of Chongqing Medical University
- Statut
- En recrutement
- Registre
- NCT06121505
-
Étude Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07677787
-
Étude Randomized, Double-Blind, Multicenter Phase III Study of RC148 in Combination With Platinum-Based Chemotherapy Versus Tislelizumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
- Hôpital
- The First Affiliated Hospital of Anhui Medical University
- Statut
- En recrutement
- Registre
- NCT07416474
-
Étude A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre Study of Almonertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based Chemoradiation Therapy
- Hôpital
- Shandong Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT04951635
-
Étude The Therapeutic Effect of Irinotecan Liposomes Combined With Cisplatin/Carboplatin for Platinum Sensitive Recurrent Small Cell Lung Cancer
- Statut
- En recrutement
- Registre
- NCT06467786
-
Étude A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07622186
-
Étude Efficacy and Safety of PD-L1 Inhibitor Rechallenge After Immune Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer: A Multicenter Real-World Study
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT07775820
-
Étude Tubeless Anesthesia in Preventing Contralateral Lung Complications in Patients Undergoing Single-Port Thoracoscopic Surgery for Early-Stage Lung Cancer: A Single-Center, Prospective, Open-Label, Randomized Controlled Trial
- Hôpital
- Fujian Medical University Union Hospital
- Statut
- En recrutement
- Registre
- NCT07024433
-
Étude Effectiveness of Perioperative Percutaneous Acupoint Acupuncture on Postoperative Sleep Disturbances in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial
- Investigateur principal
- LIna Huang · Chief Physician, Department of Anesthesiology, Shanghai First People's Hospital
- Hôpital
- Shanghai General Hospital
- Statut
- En recrutement
- Registre
- NCT07662733
-
Étude Electroacupuncture Combined With 5-HT3 Receptor Inhibitor for the Prevention of Postoperative Nausea and Vomiting in High-risk Patients Undergoing Thoracoscopic Surgery for Lung Cancer
- Investigateur principal
- Cai Xiaoyue · Associate Chief Physician
- Hôpital
- Shanghai Chest Hospital
- Statut
- En recrutement
- Registre
- NCT07515027
-
Étude Molecular Landscape of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients With Chinese Advanced Non-small Cell Lung Cancer
- Investigateur principal
- Xiaomin Niu · Principal Investigator
- Hôpital
- Shanghai Chest Hospital
- Statut
- En recrutement
- Registre
- NCT04977791
-
Étude Randomized Controlled Study on Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
- Investigateur principal
- Xinghua Cheng · Director, Head of Oncology Surgery, Clinical Professor
- Hôpital
- Shanghai Chest Hospital
- Statut
- En recrutement
- Registre
- NCT06483295
-
Étude The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
- Investigateur principal
- Xuewen Liu · Professor
- Hôpital
- Hunan Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07138755
-
Étude A Phase I Clinical Study to Explore the Safety and Efficacy of Hypervision Proton Surgery (HyPROS) for Early-stage Non-small Cell Lung Cancer
- Investigateur principal
- Shuanghu Yuan · Professor
- Hôpital
- Anhui Provincial Hospital
- Statut
- En recrutement
- Registre
- NCT07195084
-
Étude A Multicenter, Randomized, Double-blind, Phase III Clinical Study of Comparing the Efficacy and Safety of AK112 (PD-1/VEGF Bispecific Antibody) Versus Placebo as Consolidation Treatment for Patients With Limited Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07010263
-
Étude Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery
- Hôpital
- The First Hospital of Jilin University
- Statut
- En recrutement
- Registre
- NCT07439991
-
Étude An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT05099172
-
Étude Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer（ES-SCLC）.
- Investigateur principal
- Rong Yu, MD · Investigator Official Title
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT06768307
-
Étude A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT06312137
-
Étude Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) for CEA Positive Advanced Lung Cancer
- Statut
- En recrutement
- Registre
- NCT06992583
-
Étude Surgery or Radiotherapy After PD-L1 Inhibitor (TQB-2450) and Chemotherapy Induction Therapy in Patients With Limited-stage Small-cell Lung Cancer
- Investigateur principal
- Peng Zhang · Director of science and education department
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- En recrutement
- Registre
- NCT04539977
-
Étude Exploring the Neo-Adjuvant Therapy Effects on Lung Cancer Through Monitoring and Assessment of Tumor Environment (NAT-LungMate)
- Investigateur principal
- Peng Zhang · Professor
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- En recrutement
- Registre
- NCT05857800
-
Étude Multicenter, Retrospective, Observational Study of Icotinib for Post-Surgical Adjuvant Therapy in Stage IA2 High-Risk to IB Non-Small-Cell Lung Cancer With Positive EGFR-Sensitive Mutations
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT07806604
-
Étude The Shengjing Lung Cancer Cohort (SJ-LCC) Study
- Investigateur principal
- Huanhuan Chen · Shengjing Hospital of China Medical University
- Hôpital
- Shengjing Hospital
- Statut
- En recrutement
- Registre
- NCT07779005
-
Étude A Phase II Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade (PD-1/CTLA-4) in Patients With Locally Advanced Non-Small Cell Lung Cancer
- Investigateur principal
- Hui Liu · Professor
- Hôpital
- Sun Yat-sen University Cancer Center
- Statut
- En recrutement
- Registre
- NCT07103395
-
Étude LcProt: Proteomics Longitudinal Cohort Study on Lung CancerProspective Longitudinal Cohort Study of Lung Cancer Based on Peripheral Blood and Tissue Proteomics
- Investigateur principal
- Jianxing He · Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- En recrutement
- Registre
- NCT06778512
-
Étude An Apen-label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of BEBT-109 in Patients With EGFR Exon 20 Insertion Mutations in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- En recrutement
- Registre
- NCT06706713
-
Étude Short-term Effects of Preoperative Exercise in Moderate-to-high Perioperative Risk Lung Cancer Patients(PRE-EXELUCA): a Prospective Randomized Controlled Clinical Trial
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- En recrutement
- Registre
- NCT06215326
-
Étude Beamion 44: A Randomized, Open-label, Multi-center Phase IIa Platform Trial to Evaluate the Safety and Tolerability of Zongertinib Plus Platinum-based Doublet Chemotherapy With or Without Pembrolizumab (and Potential Other Combinations) in Treatment-naïve Patients With Locally Advanced/Metastatic Non-squamous NSCLC With Activating HER2 Mutations
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- En recrutement
- Registre
- NCT07486817
-
Étude A Prospective, Multicenter, Randomized Controlled, Phase II Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Investigateur principal
- Xingwen Fan · associate professor
- Hôpital
- Fudan University Shanghai Cancer Center
- Statut
- En recrutement
- Registre
- NCT06943235
-
Étude Mechanisms of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
- Investigateur principal
- Yang Fan, MD · Vice President
- Hôpital
- Peking University People's Hospital
- Statut
- En recrutement
- Registre
- NCT07359040
-
Étude A Phase II/III Clinical Study on the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Perioperative Treatment of Resectable Stage II/III Non Small Cell Lung Cancer.
- Hôpital
- Cancer Hospital of Chinese Academy of Medical Sciences
- Statut
- En recrutement
- Registre
- NCT05913089
-
Étude A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd), a B7-H3 Antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice (TPC) in Subjects With Relapsed Small Cell Lung Cancer (SCLC) (IDeate-Lung02)
- Hôpital
- China-Japan Friendship Hospital
- Statut
- En recrutement
- Registre
- NCT06203210
-
Étude Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
- Hôpital
- First Affiliated Hospital of Zhengzhou University
- Statut
- En recrutement
- Registre
- NCT06950697
-
Étude Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy
- Investigateur principal
- Guangying Zhu · Clinical Professor, Chief Physician
- Hôpital
- China-Japan Friendship Hospital
- Statut
- En recrutement
- Registre
- NCT06692972
-
Étude A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer
- Hôpital
- Nanfang Hospital
- Statut
- En recrutement
- Registre
- NCT06858813
-
Étude Cohort Studies of Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging (STRESS-LUNG)
- Investigateur principal
- Fang Wu · Professor
- Hôpital
- Xiangya Hospital of Central South University
- Statut
- En recrutement
- Registre
- NCT05477979
-
Étude Study of Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer (BRIO)
- Investigateur principal
- Fang Wu · Chief Physician, Associate Professor
- Hôpital
- Second Xiangya Hospital of Central South University
- Statut
- En recrutement
- Registre
- NCT05979818
-
Étude The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer, Including Non-small-cell Lung Cancer and Small-cell Lung Cancer With Early and Advanced Staging
- Investigateur principal
- Fang Wu · Professor
- Hôpital
- Xiangya Hospital of Central South University
- Statut
- En recrutement
- Registre
- NCT06975384
-
Étude Comprehensive Multi-Omics Analysis of Early-Stage Lung Cancer Exhibiting Distinct Phenotypes
- Investigateur principal
- Chen Chen · Associate Professor
- Hôpital
- Second Xiangya Hospital of Central South University
- Statut
- En recrutement
- Registre
- NCT06699979
-
Étude A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- En recrutement
- Registre
- NCT07412262
-
Étude A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)
- Hôpital
- Peking University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT06899126
-
Étude Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
- Hôpital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Statut
- En recrutement
- Registre
- NCT07059923
-
Étude Assessment the Association of Imaging and Tumor Microenvironment in Lung Cancer With Radiogenomics
- Hôpital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Statut
- En recrutement
- Registre
- NCT06500312
-
Étude A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Hôpital
- Chongqing University Cancer Hospital
- Statut
- En recrutement
- Registre
- NCT05956587
-
Étude The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer: a Prospective, Observationa Trial
- Hôpital
- Ruijin Hospital
- Statut
- En recrutement
- Registre
- NCT06623487
-
Étude A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
- Hôpital
- The First Affiliated Hospital of Anhui Medical University
- Statut
- En recrutement
- Registre
- NCT06564324
-
Étude Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial
- Investigateur principal
- Dong-Xin Wang · Chairman, Department of Anaesthesiology and Critical Care Medicine
- Hôpital
- Peking University First Hospital
- Statut
- En recrutement
- Registre
- NCT04209218
-
Étude Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
- Hôpital
- The First Affiliated Hospital of Nanchang University
- Statut
- Pas encore en recrutement
- Registre
- NCT04846634
-
Étude A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy
- Investigateur principal
- Ren Shengxiang · professor
- Hôpital
- Jiangsu Cancer Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07101627
-
Étude INFORM: A Prospective Interventional Study on Early Screening for Lung Cancer Using Liquid Biopsy
- Investigateur principal
- Jianxing He · Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT06422637
-
Étude Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemotherapy Combined With Immunotherapy for the Treatment of Clinical Stage IIA-IIIB (N2) Non-small Cell Lung Cancer
- Investigateur principal
- Wen-zhao ZHONG · Head of Thoracic Surgery
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07617389
-
Étude Iparomlimab and Tuvonralimab (QL1706) Combined Chemotherapy and Quad Shot Radiotherapy in First-line Treatment of Driver Gene-negative Advanced Non-small Cell Lung Cancer: a Randomized, Controlled, Phase 2, Open-label Trial.
- Hôpital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Statut
- Pas encore en recrutement
- Registre
- NCT07271602
-
Étude An Open, Multi-center Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
- Hôpital
- Third Affiliated Hospital of Harbin Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT07550842
-
Étude A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
- Hôpital
- First Affiliated Hospital of Xiamen University
- Statut
- Pas encore en recrutement
- Registre
- NCT07031154
-
Étude Exploratory Clinical Study on Microwave Ablation With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer
- Investigateur principal
- Jiayuan Sun · Chief Physician
- Hôpital
- Shanghai Chest Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06969781
-
Étude Efficacy and Safety of Septum-guided Segmentectomy for 2-3 cm Clinical Stage IA3 Peripheral Non-Small Cell Lung Cancer: A Single-Center, Prospective, Single-Arm Clinical Trial
- Investigateur principal
- Junfeng Geng · Professor
- Hôpital
- Shanghai Chest Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07780591
-
Étude An Open-label, Single-center, Phase II Study of Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer
- Hôpital
- The First Hospital of Jilin University
- Statut
- Pas encore en recrutement
- Registre
- NCT05784974
-
Étude Postoperative Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD: a Single-arm, Multicenter Study
- Investigateur principal
- Wu Nan · Professor
- Hôpital
- Peking University Cancer Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06780839
-
Étude Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
- Investigateur principal
- Chang Chen · Deputy Director of MD. PhD. Program in Thoracic Surgery, Secretary of the party committee of Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06620822
-
Étude A Multicenter Randomized Controlled Trial of an Intelligent Pulmonary Function Exercise Device Versus Usual Care for In-Hospital and Home-Based Pulmonary Rehabilitation After Lung Cancer Surgery
- Investigateur principal
- Jianxing He · Principal Investigator
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT07631520
-
Étude A Randomized Controlled Trial Evaluating the Effectiveness of a Novel Risk-Stratified Screening Strategy for Lung Cancer
- Investigateur principal
- Jianxing He · Principal Investigator
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT07078032
-
Étude A Clinical Study Evaluating the Safety and Efficacy of Golidocitinib in Patients With Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
- Investigateur principal
- Jianxing He · Director, Head of Thoracic Surgery, Principal Investigator, Clinical Professor
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT07303881
-
Étude Predictive Value of CEA and ctDNA for Postoperative Recurrence in Patients With High CEA Sensitivity Lung Cancer
- Hôpital
- Guangdong Provincial People's Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07170046
-
Étude Development of a Chest CT-Based Artificial Intelligence Model Across the Lung Cancer Care Continuum and a Prospective Randomized Crossover Reader Study of Its Clinical Decision-Support Performance
- Hôpital
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Statut
- Pas encore en recrutement
- Registre
- NCT07829640
-
Étude A Phase II/III Clinical Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)
- Hôpital
- Sun Yat-sen University Cancer Center
- Statut
- Pas encore en recrutement
- Registre
- NCT07739199
-
Étude The Effects of Acupuncture for Lung Cancer-Related Fatigue, a Clinical Trial
- Investigateur principal
- Yuanjie Sun · Doctor
- Hôpital
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- Statut
- Pas encore en recrutement
- Registre
- NCT07079072
-
Étude Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study
- Hôpital
- Ningbo No.2 Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06221462
-
Étude A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT05990127
-
Étude Randomized Clinical Trials Comparing Immunotherapy Plus Cryoablation (I-CA) Versus Cryoablation Alone for Stage I, Selected Stage IIa, Non-Small Cell Lung Cancer
- Investigateur principal
- Jiayuan Sun · Director, Department of Respiratory Endoscopy
- Hôpital
- Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
- Statut
- Pas encore en recrutement
- Registre
- NCT06580665
-
Étude Organoid-Based Drug Sensitivity Model Guided Personalized Precision Treatment for Extensive-Stage Small Cell Lung Cancer: A Prospective, Multicenter, Randomized Controlled Trial
- Hôpital
- Peking Union Medical College Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07106528
-
Étude A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT05767892
-
Étude Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
- Hôpital
- Henan Cancer Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06236997
-
Étude An Investigator-initiated Trial Evaluating the Efficacy and Safety of Anti-Trop2 Universal CAR-NK(U-CAR-NK) Cells Therapy Combined With Chemotherapy for Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
- Investigateur principal
- Qiming Wang · Professor
- Hôpital
- Henan Cancer Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06454890
-
Étude Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
- Investigateur principal
- Liu Fang · Director
- Hôpital
- Third Affiliated Hospital of Harbin Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT07398560
-
Étude Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
- Investigateur principal
- Zhang Zhi · Associate Professor
- Hôpital
- Jiangsu Cancer Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07286942
-
Étude Efficacy and Safety of Induction Chemoimmunotherapy Followed by Carbon Ion Radiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
- Investigateur principal
- Ji Yongling · PI
- Hôpital
- Zhejiang Cancer Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07035860
-
Étude A Prospective, Multicenter, Randomized Controlled Clinical Trial Comparing Bronchoscopic Thermal Vapor Ablation and Percutaneous Microwave Ablation in Patients With COPD and Early-Stage Lung Cancer: Efficacy and Safety Evaluation
- Hôpital
- Henan Provincial People's Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06929390
-
Étude Effects of Different Preoperative Oral Rehydration Protocols on Safety, Comfort, and Postoperative Outcomes in Elderly Patients Undergoing Thoracoscopic Radical Lung Cancer Surgery: A Randomized Controlled Trial
- Hôpital
- Fujian Medical University Union Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07042503
-
Étude The Impact of SGLT2i on the Outcome of Advanced Lung Cancer in Patients With Diabetes
- Investigateur principal
- Liang Zhao · Dr
- Hôpital
- Shanghai Chest Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07272057
-
Étude Phase I Study of Anti-EGFR/c-Met Bispecific Antibody MCLA-129 Combined With Befotertinib in Patients of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation To Evaluate The Safety, Pharmacokinetic Characteristics and Antitumor Activity
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT06015568
-
Étude A Single-Arm Phase II Study of Intrathecal Thiotepa Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI
- Hôpital
- Tianjin Medical University Cancer Institute & Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07778940
-
Étude A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer
- Hôpital
- The Affiliated Hospital of Qingdao University
- Statut
- Pas encore en recrutement
- Registre
- NCT07485920
-
Étude A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
- Hôpital
- The First Affiliated Hospital of Fujian Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT07771764
-
Étude Comparing the Efficiency Between Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer: a Randomized, Controlled, Open-label, Single-center Phase III Clinical Trial
- Investigateur principal
- Peng Zhang · associate professor of medicine
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT05496166
-
Étude Furmonertinib Combined With Local Therapy in Inoperable or Surgery-Refusing Early-Stage Non-Small Cell Lung Cancer:A Single-arm, Phase II Study
- Investigateur principal
- Xuefei Hu · Chief Physician
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07517640
-
Étude A Phase II Clinical Study of Adebelizumab Combined With Other Anti-tumor Treatments as a Perioperative Treatment for Resectable Non-small Cell Lung Cancer
- Hôpital
- Shanghai Pulmonary Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT07704645
-
Étude An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on the Incidence of Pulmonary Infection and Survival in Lung Cancer Patients
- Investigateur principal
- Yalei Zhang · The First Affiliated Hospital of Guangzhou Medical University
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT07142057
-
Étude Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
- Investigateur principal
- Jianxing He · Chief physician
- Hôpital
- First Affiliated Hospital of Guangzhou Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT06893354
-
Étude Phase II, Open-label, Single-arm, Prospective, Multi-center Study to Evaluate the Efficacy and Safety of Lorlatinib as Neoadjuvant Treatment in Surgically Resectable Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer (NEOLORA)
- Investigateur principal
- Yang Fan, MD · Professor of Thoracic Surgery
- Hôpital
- Peking University People's Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06682884
-
Étude The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial
- Investigateur principal
- Gang Hou · Professor
- Hôpital
- China-Japan Friendship Hospital
- Statut
- Pas encore en recrutement
- Registre
- NCT06739421
-
Étude A Multi-cohort, Open-label Phase II Study to Evaluate the Efficacy and Safety of the Anti-EGFR/c-Met Bispecific Antibody MCLA-129 in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Gene Alterations and MET Amplification.
- Hôpital
- The First Affiliated Hospital of Anhui Medical University
- Statut
- Pas encore en recrutement
- Registre
- NCT06885840
Cette page ne partage que des informations d'études publiquement enregistrées. Elle ne recommande ni n'encourage la participation à une étude. La participation est entièrement volontaire et les risques d'un traitement non approuvé sont inconnus ; contactez directement l'hôpital pour les critères d'éligibilité et les détails du consentement éclairé.
Thérapies avancées : ce qui est autorisé et ce qui est en essai
Hôpitaux disposant d'un titre de spécialité clé nationale
Afficher les fiches des hôpitaux 46 hôpitaux avec un titre de spécialité clé
Chaque ligne est un hôpital titulaire d'un titre de spécialité clinique clé nationale dans une spécialité à laquelle cette maladie est rattachée. Il s'agit d'un relevé d'inscriptions publiées, non d'une recommandation ni d'un classement.
46 hôpitaux avec un titre de spécialité clé nationale correspondant.
Les valeurs rédigées en chinois sont citées telles que publiées par la source.
Ce que rapportent les patients
Chiffres agrégés uniquement : un résultat national cité avec sa source et l'année à laquelle il se réfère. Il ne s'agit ni d'un témoignage de patient ni d'une affirmation sur une personne.
Selon le rapport de National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023) : National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.
National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).
Source : National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Niveau A
Effets indésirables rapportés
Le taux d'un effet indésirable dans un essai clinique, cité avec sa source et la date à laquelle il a été consulté. C'est un taux propre à un essai, non un taux national.
Selon le rapport de ClinicalTrials.gov results - NCT01310036 (2026-10-05) : Pneumonia (serious adverse event) — 10 / 207 (about 4.8%) participants.
Single trial: erlotinib 150 mg daily, safety population n=207, systematic assessment, MedDRA 19.1, 5% frequency threshold. It is a single-trial rate for one study population, not a national rate.
Source : ClinicalTrials.gov results - NCT01310036 — https://clinicaltrials.gov/api/v2/studies/NCT01310036 — 2026-10-05 — Niveau B
Tous les thèmes de thérapie et d'accès
Questions sur cette maladie
Nous ne pouvons pas donner d'avis médical, mais nous pouvons répondre aux questions sur cette page et sur l'organisation d'un traitement en Chine.
Codes ICD
Afficher le tableau des codes 7 codes ICD
| Version | Code | Nom dans cette version |
|---|---|---|
| ICD-10-WHO | C34 | Malignant neoplasm of bronchus and lung |
| ICD-10-WHO | C34.0 | Main bronchus |
| ICD-10-WHO | C34.1 | Upper lobe, bronchus or lung |
| ICD-10-WHO | C34.2 | Middle lobe, bronchus or lung |
| ICD-10-WHO | C34.3 | Lower lobe, bronchus or lung |
| ICD-10-WHO | C34.8 | Overlapping lesion of bronchus and lung |
| ICD-10-WHO | C34.9 | Bronchus or lung, unspecified |
Les lignes sont les entrées ICD-10 de l'Organisation mondiale de la Santé (OMS) pour cette maladie, citées telles que publiées.
Source et preuve
- URL de la source
- https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
- Schéma de la source
- https
- Type de source
- Commission provinciale de la santé
- Niveau de preuve
- A - énoncé par une commission de la santé, un institut national de recherche ou une université
- Consultée le
- 2026-09-24